Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alipogene Tiparvovec (AMT-011) in LPL-deficient Adults
NCT00891306Phase 3Completed
- Sponsor
- Amsterdam Molecular Therapeutics
- Start
- Feb 2009
- Primary completion
- Aug 2010
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alipogene tiparvovec in lipoprotein lipase deficiency (LPLD), sponsored by Amsterdam Molecular Therapeutics. Primary endpoint: Reduction of triglyceride concentrations at 12 weeks. Started Feb 2009; status: completed.
02
Drugs
alipogene tiparvovec
03
Conditions
lipoprotein lipase deficiency (LPLD)
Beyond the preview
Go deeper on NCT00891306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00891306.